Analysts’ Weekly Ratings Updates for Glaukos (GKOS)

Several analysts have recently updated their ratings and price targets for Glaukos (NYSE: GKOS):

• 5/2/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/30/2026 – Glaukos was given a new $170.00 price target by Stifel Nicolaus.
• 4/30/2026 – Glaukos had its price target raised by Citigroup Inc. from $135.00 to $140.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by JPMorgan Chase & Co. from $120.00 to $140.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by Wells Fargo & Company from $135.00 to $138.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by BTIG Research from $131.00 to $141.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Glaukos had its price target raised by Needham & Company LLC from $127.00 to $136.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Glaukos had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other news, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the sale, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at $6,115,340. This represents a 18.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Aimee S. Weisner sold 15,000 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the completion of the transaction, the director directly owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 50,930 shares of company stock valued at $6,703,263. Insiders own 6.40% of the company’s stock.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.